Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development
- PMID: 3143885
- DOI: 10.1016/0882-4010(87)90059-3
Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development
Abstract
The protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 was tested in an infant rat infection model. Four monoclonal antibodies to class 1 protein had bactericidal titres exceeding 20,000 and they protected infant rats completely against bacterial challenge with meningococci carrying the same class 1 protein, P1.16. One monoclonal antibody to class 3 protein was highly bactericidal (titer greater than 20,000), whereas two others had no bactericidal activity. All these antibodies gave some protection from infection, resulting in mortalities varying from 66 to 83% as compared to 100% in control rats who had received either unrelated monoclonal antibody or saline. These results strongly speak for class 1 outer membrane protein as a vaccine candidate for meningococcus group B.
Similar articles
-
Murine monoclonal antibodies to PorA of Neisseria meningitidis show reduced protective activity in vivo against B:15:P1.7,16 subtype variants in an infant rat infection model.Microb Pathog. 2001 Mar;30(3):139-48. doi: 10.1006/mpat.2000.0419. Microb Pathog. 2001. PMID: 11273739
-
Class 1/3 outer membrane protein vaccine against group B, type 15, subtype 16 meningococci.Dev Biol Stand. 1986;63:147-52. Dev Biol Stand. 1986. PMID: 3091433
-
The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci.Vaccine. 1999 Jun 4;17(20-21):2677-89. doi: 10.1016/s0264-410x(99)00049-3. Vaccine. 1999. PMID: 10418919
-
Meningococcal vaccines--present and future.Trans R Soc Trop Med Hyg. 1991;85 Suppl 1:37-43. doi: 10.1016/0035-9203(91)90339-z. Trans R Soc Trop Med Hyg. 1991. PMID: 1803695 Review.
-
The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.Contrib Microbiol Immunol. 1989;10:151-65. Contrib Microbiol Immunol. 1989. PMID: 2479499 Review. No abstract available.
Cited by
-
Deduced amino acid sequences of class 1 protein (PorA) from three strains of Neisseria meningitidis. Synthetic peptides define the epitopes responsible for serosubtype specificity.J Exp Med. 1990 Jun 1;171(6):1871-82. doi: 10.1084/jem.171.6.1871. J Exp Med. 1990. PMID: 1693651 Free PMC article.
-
Multiple mechanisms of phase variation of PorA in Neisseria meningitidis.Infect Immun. 2000 Dec;68(12):6685-90. doi: 10.1128/IAI.68.12.6685-6690.2000. Infect Immun. 2000. PMID: 11083782 Free PMC article.
-
A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.Infect Immun. 2002 Dec;70(12):6576-82. doi: 10.1128/IAI.70.12.6576-6582.2002. Infect Immun. 2002. PMID: 12438327 Free PMC article. Clinical Trial.
-
Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection.J Exp Med. 1997 Apr 7;185(7):1173-83. doi: 10.1084/jem.185.7.1173. J Exp Med. 1997. PMID: 9104804 Free PMC article.
-
Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.Infect Immun. 2014 Jun;82(6):2574-84. doi: 10.1128/IAI.01517-14. Epub 2014 Mar 31. Infect Immun. 2014. PMID: 24686052 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources